Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Verona Pharma plc (VRNA)

12.12   -0.49 (-3.89%) 11-28 10:57
Open: 12.6 Pre. Close: 12.61
High: 12.865 Low: 11.87
Volume: 138,238 Market Cap: 917(M)

Technical analysis

as of: 2022-11-28 10:53:11 AM
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 15.88     One year: 18.55
Support: Support1: 11.22    Support2: 9.76
Resistance: Resistance1: 13.6    Resistance2: 15.88
Pivot: 12.4
Moving Average: MA(5): 12.45     MA(20): 12.49
MA(100): 9.82     MA(250): 6.96
MACD: MACD(12,26): 0.3     Signal(9): 0.4
Stochastic oscillator: %K(14,3): 45.8     %D(3): 48.6
RSI: RSI(14): 51
52-week: High: 14.68  Low: 3.4
Average Vol(K): 3-Month: 225 (K)  10-Days: 143 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ VRNA ] has closed above bottom band by 15.6%. Bollinger Bands are 70.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 12.97 - 13.01 13.01 - 13.05
Low: 12.35 - 12.41 12.41 - 12.46
Close: 12.52 - 12.61 12.61 - 12.69

Company Description

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

Headline News

Mon, 21 Nov 2022
Rising COVID Cases in China, Plunging Oil Prices Drag European Equities Lower in Monday Trading - InvestorsObserver

Tue, 15 Nov 2022
How Much Upside is Left in Verona Pharma PLC American Depositary Share (VRNA)? Wall Street Analysts Think 110% - Nasdaq

Tue, 15 Nov 2022
Here's Why Momentum in Verona Pharma PLC American Depositary Share (VRNA) Should Keep going - Nasdaq

Thu, 10 Nov 2022
Verona Pharma ADR Earnings, Revenue Miss in Q3 By -

Wed, 09 Nov 2022
Verona Pharma plc (VRNA) Q3 2022 Earnings Call Transcript - Seeking Alpha

Sun, 06 Nov 2022
These 2022 Winning Stocks Can Keep Soaring in 2023, Say Analysts - TipRanks

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 76 (M)
Shares Float 39 (M)
% Held by Insiders 10.5 (%)
% Held by Institutions 69.9 (%)
Shares Short 855 (K)
Shares Short P.Month 606 (K)

Stock Financials

EPS -1
EPS Est Next Qtl -0.41
EPS Est This Year -2.24
EPS Est Next Year -2.64
Book Value (p.s.) 3.15
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -19.8
Return on Equity (ttm) -40.2
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0.52
Sales Per Share 0
EBITDA (p.s.) -0.99
Qtrly Earnings Growth 0
Operating Cash Flow -69 (M)
Levered Free Cash Flow -37 (M)

Stock Valuations

PE Ratio -12.21
PEG Ratio 0
Price to Book value 3.83
Price to Sales 0
Price to Cash Flow -13.16

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.